Viral Latency: The Silent Phase Before Reactivation

Latency is a reversible, non-replicative state where viral genome persists in host cells without producing infectious virions.

Key Features

  • Genome maintenance: Episomal (herpesviruses) or integrated (retroviruses).
  • Minimal gene expression: Latency-associated transcripts (LATs) only; no structural proteins.
  • Immune evasion: No viral antigens presented → invisible to CTLs.
  • Specific reservoirs: HSV → trigeminal/sacral ganglia; VZV → dorsal root ganglia; EBV → memory B cells; HIV → resting CD4+ T cells; CMV → myeloid progenitors.

Reactivation Triggers

  • Immunosuppression (steroids, chemo, HIV, transplant).
  • Stress (cortisol, catecholamines).
  • UV radiation (HSV).
  • Hormonal changes.
  • Co-infections, inflammation.

Clinical Consequences

  • Herpes: cold sores, shingles, encephalitis.
  • EBV: PTLD, lymphomas.
  • CMV: end-organ disease in transplant.
  • HIV: viral rebound if ART stopped.
  • BK virus: nephropathy in kidney transplant.

Therapeutic Implications

  • Antivirals target lytic replication (not latent genome).
  • ART suppresses HIV but doesn't eradicate reservoir.
  • Latency-reversing agents ("shock and kill") experimental for HIV cure.

Latency = persistence strategy. Understanding it is key to cure research and managing reactivation risk.

Viral Infections - Related Articles